NR4A1 and breast carcinoma: Although 80% (1,252/1,565) of ERBB2mut breast cancer is non-amplified, the approval of T-DXd for hormone receptor–positive HER2-low/-ultralow cancers may modulate the added clinical value of identifying ERBB2 mutations in this cancer type context.